Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Pharmaxis Ltd looking like an enticing target for big pharma

Wednesday, November 23, 2016 16:49
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Pharmaxis Ltd (ASX:PXS) is becoming a more enticing target for drug acquisition and partnerships as it continues to develop its fibrosis and inflammation drugs.

The company is looking to build on its prior drug commercialisation success which saw it do a deal in 2015 in with a potential value of over A$750 million.

The successful drug was to treat the liver disease, non-alcoholic steatohepatitis (NASH).

Pharmaxis is targeting LOXL2 to reduce liver fibrosis and the liver disease NASH and has received strong interest from large pharmaceutical companies.

Mergers and acquisitions are increasing in the fibrosis and NASH space and there is evidence of structural pressure on big pharma to drive this M&A trend further.

Growing M&A environment

A number of players have started consolidating the NASH space and recent business development deals have clearly been competitive auctions

The number of deals in the space has increased over the last five years.

Pharmaxis have one of the only unencumbered clinical stage assets in the anti‐fibrotic space.

The company sees it as an obvious acquisition target for consolidators looking for combination therapies.

The range of upfront/acquisition prices paid before earn outs for pre‐clinical to phase 2 assets in the last 2 years has been ~$50‐400 million.

Pharmaxis’ current enterprise value is circa $60 million.

Background

Pharmaxis is a pharmaceutical research company with a portfolio including two respiratory products approved in various world markets and a research pipeline focused on areas of high unmet clinical need in inflammatory and fibrotic diseases.

The company’s product pipeline is founded on its expertise in the chemistry of amine oxidase inhibitors.

This expertise has attracted interest from leading pharmaceutical companies looking to make acquisitions or partner in this rapidly expanding area of medical need.

In May 2015, Boehringer Ingelheim acquired the Pharmaxis phase 1 investigational drug PXS-4728A, to develop it for the treatment of the cardiometabolic liver-related condition NASH.

This involved an upfront payment of €27.5 million and a total potential deal value of over A$750 million.

Boehringer is due to pay another milestone when they commence a phase 2 trial expected in 2017.

LOXL2

Activation of LOXL2 in the human body leads to fibrosis. Pharmaxis is targeting LOXL2 to reduce liver fibrosis and the liver disease NASH.

Competing drugs are about to enter phase 3 and are attracting attention due to their stage of development but there is no sense that these drugs will be a solution.

A significant number of big pharma companies are investing in the NASH space with Deutsche Bank forecasting the NASH market to be valued at $35 billion by 2025.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Total 1 comment
  • “A significant number of big pharma companies are investing in the NASH space with Deutsche Bank forecasting the NASH market to be valued at $35 billion by 2025.”

    Yes, because Deutsche Bank has proven to show incredibly integrity when talking about actual value, particularly when they’re desperate.

    Sometimes I think economists are the most retarded people on the planet.

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.